Recursion Pharmaceuticals Stock Today

RXRX Stock  USD 8.01  1.42  21.55%   

Performance

3 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Less than 19

 
High
 
Low
Low
Recursion Pharmaceuticals is trading at 8.01 as of the 7th of December 2024; that is 21.55 percent increase since the beginning of the trading day. The stock's open price was 6.59. Recursion Pharmaceuticals has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of January 2023 and ending today, the 7th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of April 2021
Category
Healthcare
Classification
Health Care
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company has 381.9 M outstanding shares of which 64.57 M shares are at this time shorted by private and institutional investors with about 12.25 trading days to cover. More on Recursion Pharmaceuticals

Recursion Stock Highlights

ESG Sustainability
Environmental
Governance
Social
COO PresidentTina Larson
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.07160.0682
Sufficiently Up
Slightly volatile
Total Current Liabilities59.4 M93.2 M
Way Down
Slightly volatile
Non Current Liabilities Total149.4 M97.1 M
Way Up
Pretty Stable
Total Assets520.4 M653.7 M
Significantly Down
Slightly volatile
Total Current Assets415.5 M438.1 M
Notably Down
Slightly volatile
Debt Levels
Recursion Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Recursion Pharmaceuticals' financial leverage. It provides some insight into what part of Recursion Pharmaceuticals' total assets is financed by creditors.
Liquidity
Recursion Pharmaceuticals currently holds 50.67 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Recursion Pharmaceuticals has a current ratio of 5.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Recursion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

13.27 Million
Recursion Pharmaceuticals (RXRX) is traded on NASDAQ Exchange in USA. It is located in 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 and employs 500 people. Recursion Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.56 B. Recursion Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 381.9 M outstanding shares of which 64.57 M shares are at this time shorted by private and institutional investors with about 12.25 trading days to cover. Recursion Pharmaceuticals currently holds about 515.44 M in cash with (287.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98.
Check Recursion Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Recursion Pharmaceuticals owns a total of 381.9 Million outstanding shares. Over half of Recursion Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Recursion Ownership Details

Recursion Stock Institutional Holders

InstituionRecorded OnShares
Nvidia Corp2024-09-30
7.7 M
Data Collective Iv Gp, Llc2024-09-30
5.9 M
Geode Capital Management, Llc2024-09-30
5.4 M
Dcvc Opportunity Fund Ii Gp, Llc2024-09-30
M
Exor Investments (uk) Llp2024-09-30
3.7 M
Deerfield Management Co2024-09-30
2.3 M
Ubs Asset Mgmt Americas Inc2024-09-30
2.1 M
Northern Trust Corp2024-09-30
M
Norges Bank2024-06-30
1.9 M
Ark Investment Management Llc2024-09-30
32.8 M
Baillie Gifford & Co Limited.2024-09-30
25.2 M
View Recursion Pharmaceuticals Diagnostics

Recursion Pharmaceuticals Historical Income Statement

At this time, Recursion Pharmaceuticals' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 19.2 M in 2024, whereas Interest Expense is likely to drop slightly above 92.2 K in 2024. View More Fundamentals

Recursion Stock Against Markets

Recursion Pharmaceuticals Corporate Management

Christopher GibsonCEO CoFounderProfile
Kevin LeggatVice AccountingProfile
Janelle GordonVice OperationsProfile
Shafique MDInterim OfficerProfile
Nathan HatfieldChief OfficerProfile

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.